NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

The NEAT trial reported considerable benefit for ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil) of 28% for relapse-free survival (RFS) and 30% for overall survival (OS), when compared with classical CMF in early breast cancer. To assess tolerability, toxicity, dose i...

Descripción completa

Detalles Bibliográficos
Autores principales: Earl, H M, Hiller, L, Dunn, J A, Bathers, S, Harvey, P, Stanley, A, Grieve, R J, Agrawal, R K, Fernando, I N, Brunt, A M, McAdam, K, O'Reilly, S, Rea, D W, Spooner, D, Poole, C J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570521/
https://www.ncbi.nlm.nih.gov/pubmed/18797468
http://dx.doi.org/10.1038/sj.bjc.6604674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570521/
https://www.ncbi.nlm.nih.gov/pubmed/18797468
http://dx.doi.org/10.1038/sj.bjc.6604674

Ejemplares similares